News and Media
News and Media
BioAlliance Pharma collaborates with Penn Pharma on the industrial development of Validive®
March 31, 2014
Sitavig® Licensing Strategy: Execution of licensing agreement with Innocutis for North America and Positive opinion from French and German Health Authorities for Marketing Authorization
March 19, 2014
Strengthening and extension of the industrial protection of Livatag® until 2031 – First delivery of a new European patent
February 18, 2014
BioAlliance Pharma’s partner, Sosei, announces a partnership with FUJIFILM Pharma for commercialization rights for Loramyc® in Japan
February 4, 2014
FDA grants Validive® (clonidine Lauriad®) with a Fast Track Designation for the prevention and treatment of oral mucositis induced by anticancer treatments
January 23, 2014
Quarterly information as of September 30, 2013
November 14, 2013
Key milestones and consolidated accounts First semester 2013
September 19, 2013
Bioalliance Pharma updates on major achievements of 2012 and publishes its 2012 consolidated financial statements and income for Q1 2013
April 15, 2013
Quarterly information as of September 30, 2012 • A dynamic progression of BioAlliance Pharma portfolio Orphan
November 14, 2012
Key milestones and consolidated accounts for the first semester of 2012
September 13, 2012
Full-year financial results for 2011 • Q1 2012 Consolidated turnover
April 17, 2012
2011 achievements and 2012 prospects
January 26, 2012
BioAlliance Pharma reports its consolidated turnover for Q3 And announces progress for Loramyc® commercialization in Italy
November 14, 2011
Consolidated accounts for the first semester of 2011 and recent significant key events
September 21, 2011
Q2 2011: BioAlliance Pharma accelerates the progress of its “Orphan oncology products” portfolio and pursues its international partnerships on its “Specialty products”
July 28, 2011
Press Release Signup
Subscribe to receive our Press Releases when they come out.
